All In Biotech

NDA 021314 · Meridian Bioscience

Idkit:Hp

Citric Acid, Urea C-13 · Oral · Helicobacter pylori Diagnostic

Last checked: Nov 20, 2026Latest source record: Jul 24, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2002

Dec 17, 2002

Approved uses

2

Original approval plus efficacy supplements

Registered trials

516

148 Phase 3, 44 recruiting

FAERS reports

0

0 serious, 0 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Jul 28, 2026.

IDkit Hp ® One and IDkit Hp ® Two are indicated for use as a diagnostic aid in the initial diagnosis and post-treatment monitoring of Helicobacter pylori (H. pylori) infection in adults and pediatric patients 3 years of age and older. IDkit Hp One and IDkit Hp Two are to be administered only by trained personnel as ordered by a licensed healthcare practitioner using the BreathID ® system device as identified in the BreathID ® system device labeling. IDkit Hp One and IDkit Hp Two are indicated for use as a diagnostic aid in the initial diagnosis and post-treatment monitoring of Helicobacter pylori (H. pylori) infection in adults and pediatric patients 3 years of age and older. ( 1 ) IDkit Hp One and IDkit Hp Two are to be administered only by trained personnel as ordered by a licensed healthcare practitioner using the BreathID ® system device as identified in the BreathID ® system device labeling. ( 1 )

Mechanism: IDkit Hp One and IDkit Hp Two are administered using the BreathID system device, a non-invasive breath test that analyzes a breath sample before and after ingestion of 13 C- urea and citric acid. 75 mg 13 C-urea and 4. g citric acid is dissolved in water and administered orally to the patient. The presence of citric acid creates an acidic environment in the stomach and delays the gastric emptying of the ingested solution to the duodenum. These two characteristics facilitate the decomposition of the urea by H. pylori , if present. Thus, in the presence of urease produced by gastric H. pylori ,...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • IDKIT:HP · CITRIC ACID 4GM; UREA C-13 75MG · FOR SOLUTION, TABLET, FOR SOLUTION, ORAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Citric Acid" as an intervention, any sponsor and status, largest first.

All 516 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals

No FAERS reports name this application.

FAERS reports by year

By the date FDA received the report.

No reports.

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 506 on PubMed

Sponsor: Meridian Bioscience

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.